Key Highlights

  • Encaleret is a BridgeBio Pharma (NASDAQ:BBIO) drug for autosomal dominant hypocalcemia type 1, not a Biohaven product, so an October 12, 2026 report that credited Biohaven appears to be mistaken.
  • BridgeBio (NASDAQ:BBIO) reported Phase 3 CALIBRATE results in which 76% of patients met the primary endpoint in its late October 2025 topline report, per company materials.
  • Additional CALIBRATE evidence on bone turnover and patient-reported symptoms is scheduled for the 2026 meeting of the American Society for Bone and Mineral Research. Patient symptoms matter for approval.
  • Efficacy figures for the October 12, 2026 report were not captured, so this article relies on earlier company disclosures and should be checked against the latest release.

Correcting the Attribution

The October 12, 2026 report asked whether Biohaven's encaleret succeeded in Phase 3 for a rare calcium-regulation disorder. Company materials show that encaleret is developed by BridgeBio Pharma (NASDAQ:BBIO), not by Biohaven, so the attribution appears wrong. The drug targets autosomal dominant hypocalcemia type 1, a genetic condition in which the calcium-sensing receptor responds at too low a level, so the body loses calcium in urine and blood calcium runs low. BridgeBio (NASDAQ:BBIO) has described Phase 3 CALIBRATE results, and the new data on bone turnover and symptoms are planned for a bone research meeting in 2026. The exact text of the October 12 release was not reviewed.

What the Trial Showed

In the company's late October 2025 topline report, 76% of encaleret patients met the primary endpoint of reaching normal blood calcium without excess urinary calcium while reducing standard therapy, per company materials. The comparator results and the trial size were not captured in published information, so no comparison is made. Encaleret works by correcting the signal of the calcium-sensing receptor, which standard care of calcium and active vitamin D only works around. The more recent data on bone turnover and symptoms address whether biochemical gains translate into patients feeling better and into healthier bone. Standard care is lifelong and does not fix the receptor problem.

Risks and What to Watch

Investors in BridgeBio (NASDAQ:BBIO) will watch for the regulatory submission, which the company has said it plans for 2026, according to its materials, and for safety follow-up. Risks include regulatory delays, differences between trial and real-world patients, pricing and reimbursement for a rare-disease treatment and cash needs. A rare-disease market is small, so revenue depends on diagnosis rates and payer coverage. This article is a correction and background, not a report of new Phase 3 numbers, and any figure here should be confirmed against the latest release. Rare-disease drugs often win approval on biochemical measures, but payers want evidence on patient outcomes. Cash needs for launch preparation are a further factor.

Where Things Stand

Encaleret did show success in Phase 3, but it is a BridgeBio (NASDAQ:BBIO) drug and the Biohaven credit looks wrong. The 76% primary endpoint rate comes from the company's October 2025 topline report, and new data on bone and symptoms are due at a 2026 meeting. BridgeBio (NASDAQ:BBIO) will need regulatory review before encaleret can reach patients. Because the report named the wrong company, the safest answer is to treat October 12 details as unconfirmed and rely on the sponsor's own release for numbers on the program. The firm will also need a commercial plan for a very small patient population.